{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:14:56Z","timestamp":1773249296594,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":792,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1111\/apt.12389","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T01:41:38Z","timestamp":1372729298000},"page":"365-376","source":"Crossref","is-referenced-by-count":40,"title":["Meta-analysis: rapid infliximab infusions are safe"],"prefix":"10.1111","volume":"38","author":[{"given":"H. C.","family":"Neef","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology; Department of Pediatrics and Communicable Diseases; University of Michigan; Ann Arbor; MI; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Riebschleger","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology; Department of Pediatrics and Communicable Diseases; University of Michigan; Ann Arbor; MI; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Adler","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology; Department of Pediatrics and Communicable Diseases; University of Michigan; Ann Arbor; MI; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"key":"10.1111\/apt.12389-BIB0001|apt12389-cit-0001","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1572-0241.2007.01094.x","article-title":"The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients","volume":"102","author":"Feagan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/apt.12389-BIB0002|apt12389-cit-0002","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"Brit J Dermatol"},{"key":"10.1111\/apt.12389-BIB0003|apt12389-cit-0003","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/apt.12389-BIB0004|apt12389-cit-0004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/apt.12389-BIB0005|apt12389-cit-0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12389-BIB0006|apt12389-cit-0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MPG.0b013e31828f1ea2","article-title":"Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease","volume":"57","author":"Adler","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1111\/apt.12389-BIB0007|apt12389-cit-0007","unstructured":"Remicade (Infliximab) prescribing information [package insert] Horsham, PA Janssen Biotech, Inc. 2013"},{"key":"10.1111\/apt.12389-BIB0008|apt12389-cit-0008","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/01.mjt.0000245223.43783.45","article-title":"Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting","volume":"13","author":"Ollendorf","year":"2006","journal-title":"Am J Ther"},{"key":"10.1111\/apt.12389-BIB0009|apt12389-cit-0009","doi-asserted-by":"crossref","first-page":"313","DOI":"10.18553\/jmcp.2011.17.4.313","article-title":"Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis","volume":"17","author":"Wong","year":"2011","journal-title":"JMCP"},{"key":"10.1111\/apt.12389-BIB0010|apt12389-cit-0010","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/ajg.2011.211","article-title":"The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety","volume":"106","author":"Van","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/apt.12389-BIB0011|apt12389-cit-0011","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease","volume":"1","author":"Behm","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/apt.12389-BIB0012|apt12389-cit-0012","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12389-BIB0013|apt12389-cit-0013","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.12389-BIB0014|apt12389-cit-0014","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium","volume":"11","author":"Jacobstein","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/apt.12389-BIB0015|apt12389-cit-0015","doi-asserted-by":"crossref","first-page":"A402","DOI":"10.1016\/S0016-5085(08)61877-6","article-title":"One hour infiximab infusion can replace two hour infusion in maintenance treatment of Crohns disease without shortcomings, in patients treated for up to three years","volume":"134","author":"Befrits","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12389-BIB0016|apt12389-cit-0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clinre.2012.07.004","article-title":"Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer?","volume":"37","author":"Belhassan","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1111\/apt.12389-BIB0017|apt12389-cit-0017","first-page":"97","article-title":"Infliximab infusion therapy in inflammatory arthritis: assessment of the accelerated infusion protocol in comparison to the standard infusion approach","volume":"50","author":"Miedany","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/apt.12389-BIB0018|apt12389-cit-0018","first-page":"A212","article-title":"A rapid one-hour infusion of infliximab is well-tolerated gastroenterology","volume":"130","author":"Rojany","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12389-BIB0019|apt12389-cit-0019","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/S0016-5085(11)61107-4","article-title":"Accelerated infliximab infusion protocols are safe","volume":"140","author":"Saxena","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.12389-BIB0020|apt12389-cit-0020","first-page":"667","article-title":"Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis","volume":"29","author":"Shergy","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1111\/apt.12389-BIB0021|apt12389-cit-0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1699-258X(07)73616-1","article-title":"Rapid application of infliximab. Efficacy complications","volume":"3","author":"Ba\u00f1uelos-Ram\u00edrez","year":"2007","journal-title":"Reumatol Clin"},{"key":"10.1111\/apt.12389-BIB0022|apt12389-cit-0022","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/ibd.21279","article-title":"Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?","volume":"16","author":"Bhat","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/apt.12389-BIB0023|apt12389-cit-0023","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/ajg.2011.61","article-title":"Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study","volume":"106","author":"Breynaert","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/apt.12389-BIB0024|apt12389-cit-0024","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/rheumatology\/kei247","article-title":"Shortening infusion times for infliximab administration","volume":"45","author":"Buch","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/apt.12389-BIB0025|apt12389-cit-0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MEG.0b013e3283081afe","article-title":"Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease","volume":"21","author":"Clare","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/apt.12389-BIB0026|apt12389-cit-0026","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2011.04699.x","article-title":"A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study","volume":"34","author":"Lee","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/apt.12389-BIB0027|apt12389-cit-0027","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/MPG.0b013e31818e1914","article-title":"Rapid infliximab infusions in pediatric inflammatory bowel disease","volume":"49","author":"Yeckes","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1111\/apt.12389-BIB0028|apt12389-cit-0028","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/apt.12389-BIB0029|apt12389-cit-0029","unstructured":"Wells GA Shea B O'Connell D et\u00a0al The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"10.1111\/apt.12389-BIB0030|apt12389-cit-0030","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1111\/apt.12389-BIB0031|apt12389-cit-0031","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s12325-009-0069-7","article-title":"Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients","volume":"26","author":"Kane","year":"2009","journal-title":"Adv Ther"},{"key":"10.1111\/apt.12389-BIB0032|apt12389-cit-0032","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12325-011-0048-7","article-title":"Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs","volume":"28","author":"Carter","year":"2011","journal-title":"Adv Ther"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12389","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/apt.12389\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T17:18:03Z","timestamp":1625419083000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1111\/apt.12389","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,1]]}}}